Core Viewpoint - Viatris Inc. has acquired Aculys Pharma, enhancing its portfolio in the Central Nervous System (CNS) therapy area with exclusive rights to develop and commercialize pitolisant and Spydia in Japan, targeting significant unmet medical needs [1][4][8] Acquisition Details - The acquisition includes exclusive development and commercialization rights for pitolisant in Japan, which is on track for marketing approval by the end of 2025 for treating excessive daytime sleepiness (EDS) and cataplexy in narcolepsy patients [2][4] - Viatris also acquired exclusive rights for Spydia Nasal Spray in Japan and certain Asia-Pacific markets, which was approved in June 2025 for treating status epilepticus [3][10] Strategic Alignment - The acquisition leverages Viatris' existing commercial infrastructure and expertise in CNS, aligning with its strategy to target accretive regional business development opportunities [4][8] - Viatris aims to expand its innovative product portfolio in Japan, which includes other products under regulatory review or in pivotal Phase 3 trials [4][14] Financial Terms - The acquisition agreement includes an upfront payment to Aculys Pharma shareholders, with additional payments contingent on achieving specified regulatory and commercial milestones, along with royalties on net sales [5][14] Clinical Trial Results - Recent Phase 3 clinical trial results in Japanese patients for pitolisant showed significant improvement in EDS compared to placebo, with no serious adverse events reported [7][9][14] - The OSAS Phase 3 trial demonstrated statistically significant improvement in EDS for patients receiving pitolisant, consistent with global clinical study results [9][14] Product Information - Pitolisant is a selective/inverse agonist of the histamine H3 receptor, approved in multiple countries for narcolepsy and OSAS, with a strong safety profile [6][14] - Spydia Nasal Spray is the first intranasal anti-seizure medication approved in Japan for status epilepticus, marking a significant advancement in treatment options [10][11]

Core Insights - Viatris Inc. has been recognized on Forbes' list of World's Best Employers 2025 for the fifth consecutive year, highlighting its commitment to employee wellbeing and inclusivity [1][2]. Company Recognition - The inclusion in Forbes' list is a significant milestone as the company approaches its fifth anniversary, reflecting the dedication of its employees in creating a supportive workplace [2]. - Viatris has also been recognized in other prestigious lists, including TIME's World's Most Sustainable Companies 2024 and Forbes' World's Top Companies for Women 2024, along with various certifications such as Great Place to Work and Top Employers in multiple countries [2]. Survey Methodology - The World's Best Employers were selected based on an independent survey involving over 300,000 participants across 50 countries, who rated their employers on a scale of 1 to 10 and provided feedback on various employment aspects [2]. Company Overview - Viatris is a global healthcare company that aims to bridge the gap between generics and brand-name medications, providing access to high-quality medicines for approximately 1 billion patients annually [3]. - The company is headquartered in the U.S. and has global centers in Pittsburgh, Shanghai, and Hyderabad, India, focusing on addressing significant health challenges worldwide [3].

Core Viewpoint - Viatris shares experienced a decline after six consecutive sessions of gains, closing at $10.13, which is a 0.6% decrease [1] Summary by Relevant Sections - **Stock Performance** - The stock gained 7% over the previous six sessions [1] - Year-to-date, the stock has lost over 13% [1] - In contrast, the broader market has risen by 14% [1]

Group 1 - The Conservative Income Portfolio focuses on value stocks with high margins of safety and aims to reduce volatility through well-priced options [1][2] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - The Covered Calls Portfolio aims for lower volatility income investing with an emphasis on capital preservation [1][2] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income and capital preservation [2] - The investing group operates the Conservative Income Portfolio in partnership with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [2]

Group 1 - The Conservative Income Portfolio aims to target the best value stocks with high margins of safety while reducing volatility through well-priced options [1] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - The Covered Calls Portfolio focuses on lower volatility income investing with an emphasis on capital preservation [1] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income and capital preservation [2] - The investing group operates the Conservative Income Portfolio in partnership with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [2]

Acquisition of Metsera - Pfizer plans to acquire Metsera, Inc, with the transaction expected to close in 4Q 2025 and drive growth from the late 2020s and beyond[16] - The acquisition will be funded primarily with available cash and proceeds from new debt and is not expected to impact Pfizer's credit rating[19] - The enterprise value is based on Metsera's June 30 reported cash balance of approximately $500 million[19] Pipeline and Clinical Trials - Pfizer and Roche have a global collaboration for the p40 x TL1A bispecific antibody (PF-07261271)[23] - Pivotal trials are ongoing or initiation is planned before or during 1H 2026 for several drug candidates[22] - MET-097i is a fully biased ultra-long-acting next-generation GLP-1 receptor agonist[33] MET-097i Clinical Data - In a Phase 2a trial, a monthly dose of MET-097i after 12 weekly doses was well tolerated with continued weight loss observed[38] - Phase 1 data demonstrate robust efficacy and placebo-like tolerability at potential starting doses for MET-233i[41] - Placebo-adjusted weight change in adherence to treatment subgroup was -14.2% with 1.2 mg → 4.8 mg of MET-097i[40] Market Opportunity - Obesity and associated conditions are on track to become among the largest pharmaceutical opportunities[27] - The acquisition aligns with Internal Medicine R&D strategy and expertise, leveraging significant primary care commercial infrastructure and field force[27] - The deal structure is risk-managed using a Contingent Value Right (CVR), sharing risk and upside with Metsera shareholders[28] - The acquisition has the potential for attractive returns for Pfizer shareholders[28] - The acquisition targets a market impacting over 1 billion lives globally[48]

Core Viewpoint - Viatris (NASDAQ: VTRS) experienced a 2.93% increase in stock price on Wednesday, reaching $9.84, after a significant decline over the previous seven trading sessions [1] Summary by Relevant Sections - Stock Performance - Over the past seven trading days, VTRS stock declined approximately 9% [1] - Notable daily losses included a 3.61% drop on September 15 and a 2.06% slide on September 12 [1]

Core Viewpoint - The healthcare industry is currently facing significant challenges, with large-cap pharmaceutical companies particularly affected, leading to a poor performance compared to the market [2][3]. Group 1: Industry Challenges - The healthcare sector has only outperformed the market during downturns over the last decade, indicating a troubling trend [2]. - The current dynamics in the healthcare industry are described as the worst experienced in decades, with managed care and pharmaceuticals identified as the main contributors to market pressures [3]. Group 2: Investment Opportunities - A methodology was employed to identify cheap healthcare stocks, focusing on companies with a market capitalization above $2 billion and a forward P/E ratio below 15 [5]. - The article lists 12 healthcare stocks deemed attractive for investment, based on their valuation metrics and growth potential [6]. Group 3: Company Highlights - **Bausch Health Companies Inc. (NYSE:BHC)**: - Forward P/E Ratio: 1.45, recognized for strategic acquisitions and pipeline developments, particularly in hepatology [7]. - Recent acquisition of DURECT Corporation valued at $63 million upfront, with potential milestone payments of up to $350 million, enhancing its portfolio for alcoholic hepatitis [8]. - Key pipeline assets include larsucosterol and rifaximin SSD, with significant market potential in addressing hospitalizations for alcoholic hepatitis [9][10]. - **Organon & Co. (NYSE:OGN)**: - Forward P/E Ratio: 2.73, focused on women's health and biosimilars, expanding its market presence since spinning off from Merck [11]. - Recent FDA approvals for biosimilars BILDYOS and BILPREVDA, aimed at improving access to osteoporosis and bone cancer treatments [12]. - The company is pivoting towards biosimilars as a growth engine while maintaining focus on women's health and dermatology [13]. - **Viatris Inc. (NASDAQ:VTRS)**: - Forward P/E Ratio: 4.40, formed from the merger of Mylan and Pfizer's Upjohn division, focusing on generics and specialty pharmaceuticals [14]. - FDA approval of a generic iron sucrose injection, reflecting a strategic entry into the intravenous iron market with significant sales potential [15]. - Positive late-stage trial results for several pipeline assets, reinforcing the company's growth strategy and upcoming product launches [16][17].

Company Overview - Theravance Biopharma's shares have increased by approximately 9.8% since the last earnings report, outperforming the S&P 500 [1] - The company reported a narrower than expected adjusted net loss of 8 cents per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of 14 cents [3] - Total revenues for Q2 2025 reached $26.2 million, significantly exceeding the Zacks Consensus Estimate of $17 million, and representing an 83.2% year-over-year increase [4] Revenue Breakdown - The revenue growth was driven by increased collaboration revenues from partner Viatris and licensing revenues [4] - Collaboration revenues from Viatris related to Yupelri sales amounted to $18.7 million, reflecting a 31% year-over-year increase [5] - Theravance received a milestone payment of $7.5 million from Viatris following the approval of Yupelri in China [5] Expense Analysis - Research and development expenses (excluding share-based compensation) totaled $9.5 million, an increase of nearly 8% from the previous year [6] - Selling, general and administrative expenses (excluding share-based compensation) rose approximately 16.4% year-over-year to $12.8 million [6] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities worth $338.8 million, up from $130.9 million as of March 31, 2025 [6] Financial Guidance - Theravance reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses in the range of $32-$38 million and adjusted SG&A expenses between $50 million and $60 million [7] - The company anticipates share-based compensation expenses of $18-$20 million in 2025 and expects adjusted losses and cash burn to be similar to 2024 levels [7] Market Sentiment - There has been a positive trend in fresh estimates, with the consensus estimate shifting by 36.84% recently [8] - Theravance holds a Growth Score of A but has a lower Momentum Score of C, with an overall VGM Score of A [10] - The stock has a Zacks Rank of 3 (Hold), indicating an expectation of an in-line return in the coming months [11] Industry Comparison - Theravance operates within the Zacks Medical - Drugs industry, where another player, United Therapeutics, has seen a 28% gain over the past month [12] - United Therapeutics reported revenues of $798.6 million for the last quarter, reflecting an 11.7% year-over-year increase, with an EPS of $6.41 compared to $5.85 a year ago [12]

Company Overview - Viatris Inc. is a global healthcare company that bridges the gap between generics and brand-name pharmaceuticals, aiming to address healthcare needs worldwide [3] - The company provides access to high-quality medicines for approximately 1 billion patients annually, covering a wide range of health conditions from birth to end-of-life care [3] - Viatris has a diverse portfolio of medicines and a unique global supply chain designed to reach patients effectively [3] Leadership Changes - Andrew Enrietti has been appointed as the Chief Administrative and Transformation Officer, bringing over 20 years of experience, including 10 years at Viatris [1][2] - The CEO of Viatris, Scott A. Smith, expressed confidence in Enrietti's ability to drive the company's strategic review and long-term growth [2] - Enrietti emphasized the opportunity to shape the future of Viatris by integrating critical functions to support transformation and growth [2]